Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer

ADAM-ARTIGUES, ANNA; Brasó-Maristany, Fara; Cervera Vidal, Raimundo; Tormo, Eduardo; Arribas López, Joaquin Vicente; Arenas Lahuerta, Enrique Javier; Martínez-Sabadell, Alex

dc.contributor	Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author	ADAM-ARTIGUES, ANNA
dc.contributor.author	Brasó-Maristany, Fara
dc.contributor.author	Cervera Vidal, Raimundo
dc.contributor.author	Tormo, Eduardo
dc.contributor.author	Arribas López, Joaquin Vicente
dc.contributor.author	Arenas Lahuerta, Enrique Javier
dc.contributor.author	Martínez-Sabadell, Alex
dc.date.accessioned	2022-09-09T07:25:07Z
dc.date.available	2022-09-09T07:25:07Z
dc.date.issued	2022-05-20
dc.identifier.citation	Adam-Artigues A, Arenas EJ, Martínez-Sabadell A, Brasó-Maristany F, Cervera R, Tormo E, et al. Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer. Sci Adv. 2022 May 20;8(20):eabk2746.
dc.identifier.issn	2375-2548
dc.identifier.uri	https://hdl.handle.net/11351/8085
dc.description	Càncer de mama; Heterodimerització
dc.description.sponsorship	A.A.-A., E.J.A., and F.B.-M. were supported by Asociación Española contra el Cáncer AECC (PRDVA18013LLUC to A.A.-A., POSTD211413AREN to E.J.A., and AECC_Postdoctoral17-1062 to F.B.-M.). A.M.-S. was funded by the Spanish Government (PFIS FI20/00188). J.Ar. is supported by Breast Cancer Research Foundation (BCRF-20-08), Instituto de Salud Carlos III Project reference number AC15/00062, and the EC under the framework of the ERA-NET TRANSCAN-2 initiative cofinanced by FEDER, Instituto de Salud Carlos III (CB16/12/00449 and PI19/01181), and Asociación Española Contra el Cáncer (AECC). A.P. was supported by Instituto de Salud Carlos III—PI19/01846, Breast Cancer Now—2018NOVPCC1294. P.E. and A.L. were funded by Instituto de Salud Carlos III and cofinanced by FEDER (PI18/01219 to P.E. and CB16/12/00481 to A.L.). J.M.C. was funded by Sociedad Española de Oncología Médica (Rio Hortega-SEOM) and Compromiso ADAMED.
dc.language.iso	eng
dc.publisher	American Association for the Advancement of Science
dc.relation.ispartofseries	Science Advances;8(20)
dc.rights	Attribution-NonCommercial 4.0 International
dc.rights.uri	http://creativecommons.org/licenses/by-nc/4.0/
dc.source	Scientia
dc.subject	Mama - Càncer - Tractament
dc.subject	Resistència als medicaments
dc.subject.mesh	Breast Neoplasms
dc.subject.mesh	/drug therapy
dc.subject.mesh	Drug Resistance, Neoplasm
dc.title	Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer
dc.type	info:eu-repo/semantics/article
dc.identifier.doi	10.1126/sciadv.abk2746
dc.subject.decs	neoplasias de la mama
dc.subject.decs	/farmacoterapia
dc.subject.decs	resistencia a los antineoplásicos
dc.relation.publishversion	http://dx.doi.org/10.1126/sciadv.abk2746
dc.type.version	info:eu-repo/semantics/publishedVersion
dc.audience	Professionals
dc.contributor.organismes	Institut Català de la Salut
dc.contributor.authoraffiliation	[Adam-Artigues A, Cervera R] INCLIVA Biomedical Research Institute, Valencia, Spain. [Arenas EJ] Preclinical Research Program, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Center for Biomedical Network Research on Cancer (CIBERONC), Madrid, Spain. [Martínez-Sabadell A] Preclinical Research Program, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Brasó-Maristany F] August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain. Department of Medical Oncology, Hospital Clinic de Barcelona, Barcelona, Spain. [Tormo E] INCLIVA Biomedical Research Institute, Valencia, Spain. Center for Biomedical Network Research on Cancer (CIBERONC), Madrid, Spain. [Arribas J] Preclinical Research Program, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Center for Biomedical Network Research on Cancer (CIBERONC), Madrid, Spain. Cancer Research Program, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain. Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, Bellaterra, Spain. Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain
dc.identifier.pmid	35594351
dc.identifier.wos	000798164800004
dc.relation.projectid	info:eu-repo/grantAgreement/ES/PE2017-2020/FI20%2F00188
dc.relation.projectid	info:eu-repo/grantAgreement/ES/PE2013-2016/CB16%2F12%2F00449
dc.relation.projectid	info:eu-repo/grantAgreement/ES/PE2017-2020/PI19%2F01181
dc.rights.accessrights	info:eu-repo/semantics/openAccess